Total submissions: 36
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000004093 | SCV000218958 | pathogenic | Tay-Sachs disease | 2025-01-25 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr427Ilefs*5) in the HEXA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HEXA are known to be pathogenic (PMID: 1833974, 8490625). This variant is present in population databases (rs387906309, gnomAD 1.3%), and has an allele count higher than expected for a pathogenic variant. This premature translational stop signal has been observed in individuals with Tay-Sachs disease (PMID: 2848800, 16352452, 20301397, 24518553, 25287655). It is commonly reported in individuals of Ashkenazi Jewish ancestry (PMID: 2848800, 22975760). This variant is also known as c.1277_1278insTATC. ClinVar contains an entry for this variant (Variation ID: 3889). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Eurofins Ntd Llc |
RCV000224443 | SCV000225230 | pathogenic | not provided | 2015-04-13 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000004093 | SCV000247559 | pathogenic | Tay-Sachs disease | 2014-08-15 | criteria provided, single submitter | clinical testing | |
Center for Pediatric Genomic Medicine, |
RCV000224443 | SCV000281445 | pathogenic | not provided | 2015-06-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000004093 | SCV000328765 | pathogenic | Tay-Sachs disease | 2022-05-27 | criteria provided, single submitter | clinical testing | |
Knight Diagnostic Laboratories, |
RCV000004093 | SCV000538041 | pathogenic | Tay-Sachs disease | 2015-09-26 | criteria provided, single submitter | clinical testing | The c.1274_1277dupTATC, (p.Tyr427Ilefs*5) is a known frameshift variant that has been shown to result in the absence of mRNA. To that effect, the majority of pathogenic variants in the Ashkenazi Jewish TSD are null alleles, making it a common mechanism of disease. Moreover, this 4 basepair insertion variant has been reported in the majority of affected individuals of Ashkenazi Jewish ancestry (Myerowitz and Costigan, 1988), and has not been seen in the normal population databases (1000 Genomes, ExAc, and Exome Sequencing Project [ESP]). In summary, this variant is best classified as a recessive pathogenic variant for Tay-Sachs disease. |
Gene |
RCV000224443 | SCV000565056 | pathogenic | not provided | 2024-08-20 | criteria provided, single submitter | clinical testing | Common pathogenic variant in the HEXA gene found in the Ashkenazi Jewish population and associated with infantile onset Tay-Sachs disease (PMID: 20301397); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 8352284, 2848800, 30609409, 22975760, 25287655, 14727180, 8488832, 1830584, 2294750, 27033294, 1307230, 28503624, 21228398, 27959697, 29352662, 28333917, 30548430, 31076878, 31980526, 33083013, 33240792, 1387685, 37267771, 35586607, 35848209, 34554397, 33831955, 20301397) |
Hudson |
RCV000004093 | SCV000584094 | pathogenic | Tay-Sachs disease | 2014-07-10 | criteria provided, single submitter | research | |
Institute of Human Genetics Munich, |
RCV000004093 | SCV000680255 | pathogenic | Tay-Sachs disease | 2017-11-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000004093 | SCV000697162 | pathogenic | Tay-Sachs disease | 2017-08-21 | criteria provided, single submitter | clinical testing | Variant summary: This c.1274_1277dupTATC (p.Tyr427Ilefs) results in a premature termination codon, predicted to cause a truncated or absent HEXA protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One functional study found less than 5% b-Hexosaminidase activity in leukocytes from a patient with Tay-Sachs disease carrying this variant in compound heterozygosity with p.R510H (not in our internal database)(Udwadia-Hedge_2017). This variant was found in the large control database ExAC in 92/121426 control chromosomes at a frequency of 0.0007577, which does not exceed the maximal expected frequency of a pathogenic allele (0.0013975) in this gene. This variant has been reported as a common pathogenic variant found especially in Ashkenazi Jews population with consistent clinical and genetic data (Myerowitz_1988, Jamali_2014, Zampieri_2012). Multiple clinical labs as well as reputable databases have classified this variant as pathogenic. Taken together, this variant has been classified as pathogenic. |
Laboratory for Molecular Medicine, |
RCV000004093 | SCV000712205 | pathogenic | Tay-Sachs disease | 2017-05-18 | criteria provided, single submitter | clinical testing | The p.Tyr427IlefsX5 (NM_000520.4 c.1274_1277dupTATC) variant in HEXA is a common pathogenic variant that has been reported in many compound heterozygous and hom ozygous individuals with Tay-Sachs disease (Myerowitz 1988, Montalvo 2005, Scott 2010, Gort 2012, Zampieri 2012, Jamail 2014). It has been reported in ClinVar ( Variation ID#3889) as pathogenic by multiple laboratories. This variant has been identified in 1.3% (135/10152) of Ashkenazi Jewish chromosomes and 0.03% (48/12 6682) of European chromosomes by the Genome Aggregation Database (gnomAD, http:/ /gnomad.broadinstitute.org; dbSNP rs387906309). Although this variant has been s een in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at position 427 and le ads to a premature termination codon 5 amino acids downstream. This alteration i s then predicted to lead to a truncated or absent protein. Biallelic loss of fun ction in the HEXA gene is an established disease mechanism for Tay-Sachs disease . In summary, this variant meets criteria to be classified as pathogenic for Ta y-Sachs disease in an autosomal recessive manner based upon a predicted null eff ect and its biallelic occurrence in individuals with this disease. |
Ambry Genetics | RCV000623223 | SCV000743019 | pathogenic | Inborn genetic diseases | 2021-12-27 | criteria provided, single submitter | clinical testing | The c.1274_1277dupTATC (p.Y427Ifs*5) alteration, located in coding exon 11 of the HEXA gene, consists of a duplication of TATC at position 1274, causing a translational frameshift with a predicted alternate stop codon after 5 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from gnomAD, this allele has an overall frequency of 0.07% (210/282850) total alleles studied. The highest observed frequency was 1.29% (134/10370) of Ashkenazi Jewish alleles. This mutation is the most common Tay-Sachs disease alteration found in the Ashkenazi Jewish population (Myerowitz, 1988) and has been shown to account for approximately 80% of all mutant HEXA Ashkenazi Jewish alleles (Kaback, 1993; Scott, 2010). Based on the available evidence, this alteration is classified as pathogenic. |
Illumina Laboratory Services, |
RCV000004093 | SCV000914692 | pathogenic | Tay-Sachs disease | 2018-08-29 | criteria provided, single submitter | clinical testing | The HEXA c.1274_1277dupTATC (p.Tyr427IlefsTer5) variant results in a frameshift and is predicted to result in premature termination of the protein. Across a selection of the available literature, the p.Tyr427IlefsTer5 variant has been identified in eight probands in a homozygous state, two probands in a compound heterozygous state and in five probands with unknown zygosity (Myerowitz et al. 1988; McDowell et al. 1992; Jamali et al. 2014; Sheth et al. 2014). The c.1274_1277dupTATC (p.Tyr427IlefsTer5) the most common HEXA variant in the Ashkenazi Jewish population and accounts for approximately 80% of variant HEXA alleles in this population (Kaback et al. 2011). Segregation of the variant with the disease has been shown in at least two families (Myerowitz et al. 1988). The variant was found in 69 of 2238 controls in a heterozygous state and is reported at a frequency of 0.00157 in the European American population of the Exome Sequencing Project. Due to the potential impact of frameshift variants, the p.Tyr427IlefsTer5 variant is classified as pathogenic for hexosaminidase A deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Myriad Genetics, |
RCV000004093 | SCV001193865 | pathogenic | Tay-Sachs disease | 2019-10-18 | criteria provided, single submitter | clinical testing | NM_000520.4(HEXA):c.1274_1277dupTATC(Y427Ifs*5) is classified as pathogenic in the context of hexosaminidase A deficiency. Please note that the Y427Ifs*5 variant is associated with Tay-Sachs disease. Sources cited for classification include the following: PMID 2848800, 1307230, 1830584, 11463833, and 14727180. Classification of NM_000520.4(HEXA):c.1274_1277dupTATC(Y427Ifs*5) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. |
Centogene AG - |
RCV001250227 | SCV001424435 | pathogenic | Tay-Sachs disease, variant AB; Tay-Sachs disease | criteria provided, single submitter | clinical testing | ||
Ce |
RCV000224443 | SCV001747734 | pathogenic | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | HEXA: PVS1, PM2, PM3 |
Revvity Omics, |
RCV000004093 | SCV002024978 | pathogenic | Tay-Sachs disease | 2021-11-18 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV000004093 | SCV002506704 | pathogenic | Tay-Sachs disease | 2021-06-07 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000004093 | SCV002526129 | pathogenic | Tay-Sachs disease | 2022-05-30 | criteria provided, single submitter | clinical testing | ACMG categories: PVS1,PS4,PP5,BS1 |
Daryl Scott Lab, |
RCV000004093 | SCV002567942 | pathogenic | Tay-Sachs disease | 2022-08-22 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV000004093 | SCV002579636 | pathogenic | Tay-Sachs disease | 2021-12-03 | criteria provided, single submitter | clinical testing | |
Victorian Clinical Genetics Services, |
RCV000004093 | SCV002768489 | pathogenic | Tay-Sachs disease | 2022-03-31 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Tay-Sachs disease (MIM#272800). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0305 - Variant is present in gnomAD (v2) >=0.01 and <0.03 for a recessive condition (210 heterozygotes, 0 homozygotes). (I) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. These variants have been reported many times as pathogenic (DECIPHER). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. It is one of the most common variants to cause Tay-Sachs disease in the Ashkenazi Jewish population (ClinVar). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Institute of Human Genetics, |
RCV000004093 | SCV004032467 | pathogenic | Tay-Sachs disease | 2023-03-29 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000004093 | SCV004242410 | pathogenic | Tay-Sachs disease | 2024-01-02 | criteria provided, single submitter | clinical testing | Criteria applied: PVS1,PM3_VSTR,PM2_SUP |
Neuberg Centre For Genomic Medicine, |
RCV000004093 | SCV005042632 | pathogenic | Tay-Sachs disease | 2023-05-20 | criteria provided, single submitter | clinical testing | The frameshift c.1274_1277dup (p.Tyr427IlefsTer5) variant in the HEXA gene has been observed in individuals with Tay-Sachs disease (Vallance, Hilary et al.,2006). This variant is also known as c.1277_1278insTATC. It is commonly reported in individuals of Ashkenazi Jewish ancestry (Lazarin, Gabriel A et al.,2013). The p.Tyr427IlefsTer5 variant has been reported with allele frequency of 0.07% in gnomAD Exomes. This variant has been reported to the ClinVar database as Pathogenic (multiple submissions). This variant causes a frameshift starting with codon Tyrosine 427, changes this amino acid to Isoleucine residue, and creates a premature Stop codon at position 5 of the new reading frame, denoted p.Tyr427IlefsTer5. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants have been previously reported to be disease causing. For these reasons, this variant has been classified as Pathogenic. Enzyme analysis is recommended. |
Mayo Clinic Laboratories, |
RCV000224443 | SCV005414291 | pathogenic | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000224443 | SCV005625801 | pathogenic | not provided | 2024-02-14 | criteria provided, single submitter | clinical testing | The HEXA c.1274_1277dup (p.Tyr427Ilefs*5) variant alters the translational reading frame of the HEXA mRNA and causes the premature termination of HEXA protein synthesis. This variant has been described in the published literature as a common pathogenic variant in the Ashkenazi Jewish population (PMIDs: 14727180 (2004), 8230592 (1993), 2848800 (1988)). It has been reported in homozygous individuals with severe infantile Tay-Sachs disease (TSD) (PMIDs: 34554397 (2021), 33083013 (2020)27896118 (2014)), as well as in compound heterozygous individuals with additional pathogenic HEXA variants in juvenile TSD (PMID: 33240792 (2020)) and late onset TSD (PMID: 35848209 (2022), 31076878 (2019), 27033294 (2016)). Functional studies have shown nonsense mediated decay as the disease mechanism for the variant (PMID: 114638363 (2001)), resulting in little to no enzyme activity (PMIDs: 27896118 (2014), 2848800 (1988)). Based on the available information, this variant is classified as pathogenic. |
ARUP Laboratories, |
RCV000224443 | SCV005875597 | pathogenic | not provided | 2023-12-18 | criteria provided, single submitter | clinical testing | The HEXA c.1274_1277dup; p.Tyr427IlefsTer5 variant (rs387906309) is reported in the literature in the homozygous or compound heterozygous state in individuals affected with early-onset Tay-Sachs disease and is one of the most common pathogenic HEXA variants found in the Ashkenazi Jewish population (Bell 2011, Lazarin 2013, Myerowitz 1988, Paw 1990, Posey 2017, Toro 2020, Vissers 2017, Zeesman 2015). This variant is reported in ClinVar (Variation ID: 3889) and is found in the Ashkenazi Jewish population with an allele frequency of 1.3% (134/10,370 alleles) in the Genome Aggregation Database (v2.1.1). This variant causes a frameshift by inserting four nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay and is associated with the absence of protein in patient cells (Myerowitz 1988). Based on available information, the p.Tyr427IlefsTer5 variant is considered to be pathogenic. References: Bell CJ et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011 Jan 12;3(65):65ra4. PMID: 21228398. Lazarin GA et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med. 2013 Mar;15(3):178-86. PMID: 22975760. Myerowitz R and Costigan FC. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J Biol Chem. 1988 Dec 15;263(35):18587-9. PMID: 2848800. Paw BH et al. Frequency of three Hex A mutant alleles among Jewish and non-Jewish carriers identified in a Tay-Sachs screening program. Am J Hum Genet. 1990 Oct;47(4):698-705. PMID: 2220809. Posey JE et al. Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation. N Engl J Med. 2017 Jan 5;376(1):21-31. PMID: 27959697. Toro C et al. HEXA Disorders. GeneReviews. 2020. (https://www.ncbi.nlm.nih.gov/books/NBK1218/). PMID: 20301397. Vissers LELM et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. Genet Med. 2017 Sep;19(9):1055-1063. PMID: 28333917. Zeesman S et al. Prader-Willi syndrome and Tay-Sachs disease in association with mixed maternal uniparental isodisomy and heterodisomy 15 in a girl who also had isochromosome Xq. Am J Med Genet A. 2015 Jan;167A(1):180-4. PMID: 25287655. |
OMIM | RCV000004093 | SCV000024259 | affects | Tay-Sachs disease | 2004-03-01 | no assertion criteria provided | literature only | |
Foundation for Research in Genetics and Endocrinology, |
RCV000004093 | SCV000494223 | pathogenic | Tay-Sachs disease | 2014-09-11 | no assertion criteria provided | research | |
Reproductive Health Research and Development, |
RCV000004093 | SCV001142451 | pathogenic | Tay-Sachs disease | 2020-01-06 | no assertion criteria provided | curation | NM_000520.4:c.1274_1277dupTATC in the HEXA gene has an allele frequency of 0.013 in Ashkenazi Jewish subpopulation in the gnomAD database. This variant is located at the 11th exon (14 exons in the NM_000520.4 transcript), therefore, it is predicted to lead nonsense-mediated mRNA decay. The c.1274_1277dupTATC (p.Tyr427Ilefs*5) variant has been reported multiple times and is determiend as the most common disease-causing variant in the Ashkenazi Jewis (PMID: 20672374). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP criteria applied: PVS1; PS4; PP4 |
Centre de Biologie Pathologie Génétique, |
RCV001252517 | SCV001428274 | uncertain significance | Intellectual disability | 2019-01-01 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000224443 | SCV001798857 | likely pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000224443 | SCV001973862 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Natera, |
RCV000004093 | SCV002085670 | pathogenic | Tay-Sachs disease | 2017-03-17 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004755708 | SCV005346811 | pathogenic | HEXA-related disorder | 2024-07-16 | no assertion criteria provided | clinical testing | The HEXA c.1274_1277dupTATC variant is predicted to result in a frameshift and premature protein termination (p.Tyr427Ilefs*5). This is among the most common pathogenic variants in HEXA and is responsible for up to 80% of documented cases of Tay-Sachs Disease in the Ashkenzi Jewish population (Myerowitz et al. 1988. PubMed ID: 2848800; Kaback et al. 1993. PubMed ID: 20301397). This variant is interpreted as pathogenic. |